Last reviewed · How we verify

NCT03533543: NOAFCAMI-SH

New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in ShangHai

Completed Last updated 16 July 2024
What this trial tests

trial testing CEM in Atrial Fibrillation in 2,399 participants. Completed in 13 September 2019.

Timeline
20 May 2018
Primary endpoint
1 June 2019
13 September 2019

Quick facts

Lead sponsorShanghai 10th People's Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,399
Start date20 May 2018
Primary completion1 June 2019
Estimated completion13 September 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai 10th People's Hospital

Who can join

18 and older, any sex, with Atrial Fibrillation or Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To characterize and estimate the incidence rate of new-onset atrial fibrillation (NOAF) in patients with acute myocardial infarction (MI). To explore the prognostic influences of NOAF on MI patients' clinical outcomes. To further investigate the impact of NOAF associated characteristics on patients' clinical outcomes eithier during hospitalization or follow-up period.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry.
    Luo J, Qin X, Zhang X, Zhang Y, et al · · 2024 · cited 37× · PMID 38254086 · DOI 10.1186/s12933-024-02129-x
  2. Long-term impact of new-onset atrial fibrillation complicating acute myocardial infarction on heart failure.
    Luo J, Xu S, Li H, Li Z, et al · · 2020 · cited 34× · PMID 32578394 · DOI 10.1002/ehf2.12872
  3. Prognostic impact of stress hyperglycemia ratio in acute myocardial infarction patients with and without diabetes mellitus.
    Luo J, Xu S, Li H, Li Z, et al · · 2022 · cited 28× · PMID 35965248 · DOI 10.1016/j.numecd.2022.07.004
  4. Association of stress hyperglycemia ratio with in-hospital new-onset atrial fibrillation and long-term outcomes in patients with acute myocardial infarction.
    Luo J, Li Z, Qin X, Zhang X, et al · · 2024 · cited 23× · PMID 37712510 · DOI 10.1002/dmrr.3726
  5. Prognostic Impact of the Symptom of New-Onset Atrial Fibrillation in Acute Myocardial Infarction: Insights From the NOAFCAMI-SH Registry.
    Luo J, Liu B, Li H, Xu S, et al · · 2021 · cited 9× · PMID 34631808 · DOI 10.3389/fcvm.2021.677695
  6. Prognostic impact of new-onset atrial fibrillation in myocardial infarction with and without improved ejection fraction.
    Luo J, Qin X, Zhang X, Zhang Y, et al · · 2024 · cited 5× · PMID 38984376 · DOI 10.1002/ehf2.14956

Verify or expand the search:

Other trials of CEM

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03533543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing